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MOST of the surgical specialities can be tracked 
to the creative vision of a surgeon. Transplan-
tation is an exception. Here, the father of the 
field is succinctly defined in the dictionary as: 
"Peter Brian Medawar: a Brazilian born British 
Zoologist who at the age of 45 shared a 1960 
Nobel Prize for his work on acquired immuno-
logic tolerance" (1). 
Medawar was mysteriously overwhelming to 
many colleagues and observers, even when he 
was young. He was the son of a Lebanese father 
and an English mother-tall, athletic, abnormally 
handsome, hypnotically articulate in public, and 
politely cordial in his personal relations. In Sep-
tember 1969, at the age of 54, he had the first 
of a series of strokes. These crippled him physi-
cally but not in spirit. Although I saw Medawar 
often professionally and privately over a 22 year 
period, before and after he was disabled, this 
sporadic exposure was not enough to understand 
him. My sense is that no one did, except perhaps 
Jean, his wife for nearly 50 years. 
THE MEANING OF REJECTION 
Medawar's dazzling personality before and 
great courage after his strokes was inspirational, 
but his fame was based on the unique achieve-
ment in 1953 captured by the terse dictionary 
mention of "acquired immunologic tolerance." 
The roots leading to this accomplishment had 
fed on the blood of war. More than 12 years 
earlier, the recently wed zoologist Medawar-24 
years of age and fresh from graduate studies at 
Oxford University-was assigned to the service 
of the British surgeon, Dr. Thomas Gibson, to 
determine if skin allografts could be used to treat 
casualties from the Battle of Britain. 
First, in human studies with Gibson (2), and 
then with simple and logical rabbit experiments 
(3), Medawar showed that rejection of the skin 
was an immunologic phenomenon. This later was 
shown to be analogous to the cell-mediated de-
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layed hypersensitivity that confers immunity to 
diseases such as tuberculosis (4, 5). The principal 
evidence in the early studies was that repetitive 
grafts from the same donor were rejected more 
rapidly with each successive attempt-the sensi-
tization and donor specificity confirming an ear-
lier clinical observations by Emil Holman of Stan-
ford in skin-grafted burn victims (6). 
Once it was established that rejection was an 
immune reaction, strategies began to evolve to 
weaken the recipient immune system. By 1953, 
total body irradiation (7) and adrenal cortical 
steroids (8, 9) had been shown to delay skin 
rejection. However, this immunosuppressive effect 
was either minor if the animals survived, or lethal 
to the recipient if the grafts were spared. There 
was no margin of safety. 
THE BOMBSHELL PAPER 
In the resulting atmosphere of nihilism about 
clinical applications, a three and one-half page 
article by Billingham, Brent, and Medawar in 
the October 3, 1953 issue of Nature describing 
acquired tolerance (10), came as a blinding bea-
con of hope. The three men had learned that 
donor splenocytes could be engrafted by their 
intravenous infusion into immunologically imma-
ture mice in utero or perinatally. When these 
inoculated recipients matured, they could accept 
skin and other tissues from the donor (but from 
no other) mouse strain. 
The immune system of the recipients had been 
populated by the immunocytes of the donor, 
meaning that they were now chimeras. The race 
was on to convert this principle to humans. How-
ever, the dark side of their accomplishment soon 
was revealed by the two younger members of 
Medawar's team, Billingham and Brent (11) and 
by the Dane, Simonsen (12). The engrafted do-
nor cells could turn the tables and reject the 
defenseless recipient unless the tissue match was 
a good one. This was the dreaded graft versus 
host disease (GVHD) in which transplanted do-
nor cells attacked the recipient skin, gastrointes-
tinal tract, lungs, liver, and the bone marrow 
itself. Medawar's dream of 1953 was suddenly a 
nightmare. Or was it? 
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FIG. 1. The growth of bone marrow (right) and whole organ transplantation (left) from the 
seed planted by Peter Medawar during World War II. GVHD, Graft versus host disease. 
CLINICAL BONE MARROW TRANSPLANTATION 
On the contrary, the work took a straight line 
to clinical application (Fig. 1), after the dem-
onstration by Prehn and Main (13) that similar 
tolerance could be induced in adult mice ren-
dered immunologically defenseless by total body 
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FIG. 2. Bidirectional mechanism of whole organ graft acceptance involving a 
graft-versus-host (GVH) reaction by the bone marrow-derived donor leukocytes in 
the graft that are pitted against the whole recipient immunologic apparatus (host-
versus-graft [HVG], rejection). For conventional whole organ clinical transplantation, 
the recipient is not preconditioned. 
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FIG. 3. Explanation with the two-way paradigm (Fig. 2) 
for the poor prediction by tissue matching (HLA) of out-
come after whole organ transplantation. Rx, Treatment. 
irradiation before splenocyte (or later bone mar-
row) infusion. The recipient conditioning, known 
as cytoablation, also could be accomplished with 
myelotoxic drugs. However, as Billingham, Brent, 
and Medawar had predicted (5), donor specific 
tolerance could be induced in humans without 
GVHD only if there was a good tissue (HLA) 
match. In 1968, 15 years after the epic Billingham, 
Brent and Medawar publication (l 0), Robert Good 
-
Slowly Evolving Donor and 
Recipient-Specific Nonreactivity 
(Bidirectional Tolerance) 
FIG. 4. Strategy for donor leukocYle augmentation in re-
cipients of whole organ allografts. The bone marrow is 
given at the time of the operative transplant procedure. 
(14) and Fritz Bach (15) reported the first two 
successful human bone marrow transplants. Both 
recipients of well matched bone marrow from 
blood relatives are still alive. This was a triumph 
in which the principal clinicians were internists, 
as summarized 25 years later in the acceptance 
speech by the 1990 Nobel Laureate Donnall 
Thomas (16). 
CLINICAL WHOLE ORGAN TRANSPLANTATION 
Surgeons pursued a quite different pathway. 
Rejection of whole organs was at first construed 
as a mirror image of the Billingham-Brent-
Medawar model in that the leukocyte villains were 
the recipient rather than the donor immunocytes, 
and the defenseless allografts were the victims 
instead of the instruments of rejection. Literally 
accepted, this "one-way paradigm" provided no 
hope that whole organ transplantation would be 
feasible without first exchanging the bone marrow 
with that of the donor along the lines of the in-
ternist strategy described above. 
Despite the consequent pessimistic predictions, 
Nobel Laureate Joseph Murray of Boston showed 
in January 1959 that renal transplantation was 
feasible-after sublethal total body irradiation of 
a fraternal twin recipient, but without the donor 
bone marrow (17). Five more examples of long 
survival (two with unrelated kidney donors) was 
reported in Paris during the next three years 
on the services of Jean Hamburger (18) and 
Rene Kuss (19). 
This looked like a different tree from Medawar's 
original seed (Fig. 1), in which success was called 
graft acceptance (not tolerance), was not depend-
ent on good tissue matching, and did not have 
a threat of GVHD. Then, Murray and associates 
(20) showed that the same thing could be ac-
complished in humans pharmacologically, using 
chronic therapy with azathioprine. This observa-
tion came after extensive preclinical studies in 
dogs with Murray's young associate, Sir Roy CaIne 
of England, at the forefront (21). 
The clinical results with azathioprine were poor 
at first, no better than with total body irradiation 
(22). However, this changed dramatically in 1962 
when azathioprine was systematically combined 
with prednisone at the University of Colorado 
(22) . 
Rejection that developed despite azathioprine 
treatment could be reversed surprisingly easily 
with prednisone. More importantly, the sub-
sequent need for maintenance immunosuppres-
sion with both drugs frequently declined. The 
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same characteristic cycle of immunologic con-
frontation and resolution was soon observed with 
the liver (23), ultimately with all other trans-
planted whole organs, and with each of the in-
creasingly potent new drugs introduced during 
the next 30 years. This reproducible chain of 
events constituted the cardinal principle on which 
the new and increasingly practical field of trans-
plantation was based. Something had changed 
in the host, the graft, or both. But what? 
THE MEANING OF ORGAN "ACCEPTANCE" 
Medawar was perplexed. In 1964, commenting 
on the surprisingly good results of renal trans-
plantation using azathioprine and prednisone in 
the Colorado series, and in the Richmond, Virginia, 
series of David Hume, Medawar wrote, " ... foreign 
kidneys do sometimes become acceptable to their 
hosts for a reason other than acquired tolerance 
in a technical sense . . ." (24). As usual, his 
insight was uncanny. 
Nevertheless, 30 years and a revolution in im-
munology elapsed before the mystery of whole 
organ graft acceptance was resolved by study of 
the still-surviving early Colorado kidney and liver 
recipients. Donor leukocytes of bone marrow ori-
gin, which are part of the structure of all organ 
grafts (the so-called "passenger leukocytes"), had 
migrated from the transplanted organs and were 
found in the skin, lymph nodes, blood-every-
where throughout the recipients-as many as 30 
years later (25, 26). 
In essence, a small fragment of disseminated 
extramedullary donor bone marrow (illustrated 
schematically in Figure 2 as a bone silhouette) 
had become assimilated into the overwhelmingly 
larger immunologic network of the host. Whole 
organ transplantation involved a mutually can-
celing graft versus host as well as host versus 
graft reaction, with the ultimate development of 
reciprocal immunologic nonreactivity of both 
populations. The two components of transplan-
tation immunology originally defined separately 
by Medawar and his colleagues, at long last, had 
been joined. The secret was that they were in-
teractive. 
MILESTONES AND ENIGMAS REVISITED 
The two-way cancellation effect, illustrated in 
Figure 3 as a teeter-totter, explained how the 
tissue matching influence was blindfolded and 
rendered non predictive with whole organ trans-
plantation, explained the characteristic cycle of 
FIG. 5. Peter Brian Medawar (1915-1987). 
cnsIS and recovery that we see in our patients 
postoperatively, and made it understandable why 
GVHD usually does not occur after liver, intes-
tinal, multivisceral, and heart and lung trans-
plantation. It also explained why all whole organs 
have the inherent capability of tolerance induc-
tion. This had long been a contention of Paul 
Russell (27), the first American surgeon to work 
with Medawar. 
. In closing the once vast gap between the bone 
marrow and whole organ transplantation fields, 
the two-way paradigm of transplantation immu-
nology developed in 1992 (25) also had exposed 
a perioperative window of opportunity, during 
which unaltered HLA mismatched bone marrow 
can be given safely to whole organ recipients 
without recipient cytoablation or any deviation 
from the standard immunosuppressive strategies 
developed empirically 30 years earlier (Fig. 4). 
During the last 2 years, gross chimerism has 
thereby been produced routinely (28)-in the 
first cohort of patients to undergo HLA mis-
matched whole organ transplantation with the 
reasonable prospect of eventually becoming drug 
free. This, of course, was the final fulfillment 
of Medawar's dream. It came five years after his 
death in 1987 at the age of 72 years. 
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A MEDICAL GALILEO 
At the Transplantation Society Congress in Paris 
in 1992, I noted that almost 400 years to the 
day previously Calileo had arrived to his faculty 
position at the University of Padua. With a tele-
scope constructed by himself, he began the in-
quiries that defined the mysterious universe and 
resulted in man walking on the moon. Our Calileo 
was Peter Medawar, whose first probes into the 
biologic meaning of rejection and the universe 
of transplantation took place about 14 percent 
of the time from now, back to those medieval 
days. 
Armed with dissecting scissors, a few rabbits 
and mice in a dilapidated London laboratory-
and a remarkable brain that stayed vital even 
as its motor function was cruelly removed piece-
meal-this zoologist founded a new field that 
crossed all specialty barriers and blurred, as no 
one ever had before, the distinction between basic 
and clinical science. Small wonder that we re-
member so vividly and fondly the proud face 
illustrated in Figure 5. 
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